Agnès Guerci Bresler

Learn More
BACKGROUND Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), concerns have been raised over the fact that this drug could trigger progression to acute myeloid leukemia in some patients. DESIGN AND METHODS Ninety-five transfusion-dependent patients with lower risk(More)
  • 1